Pulse Brain · Growing Health Evidence Index
Peer-reviewed

Expression of P-REX2a is associated with poor prognosis in endometrial malignancies

Sho Takeshita, Yoriko Yamashita, Kosuke Shiomi, Nako Suzuki, Jun Yoshida, Aya Naiki‐Ito, Shugo Suzuki, Shinya Akatsuka, Shinya Toyokuni, Takashi Takahashi, Shoko Mase, Atsushi Arakawa, Mayumi Sugiura‐Ogasawara, Satoru Takahashi

Oncotarget · 2018

Read source ↗ All evidence

Summary

P-REX2a is a PTEN inhibitor that also activates Rac 1. No associations with P-REX2a and human endometrial cancers have been reported to date. In this study, we immunohistochemically analyzed 155 uterine endometrial malignancies for P-REX2a expression. The P-REX2a-positive tumors displayed worse prognosis independent of PTEN expression. Then, we transduced either P-REX2a expression vector or short hairpin RNAs targeting P-REX2a into 2 uterine endometrioid carcinoma cell lines, OMC-2 and JHUEM-14. Ectopic expression of P-REX2a led to increased cell proliferation only in the PTEN-expressing OMC-2 cells but did not show any change in the PTEN-negative JHUEM-14 cells or the P-REX2a-knockdown cells. Induction of P-REX2a increased and knockdown of P-REX2a decreased cell migration in both cell lin

Source type
Peer-reviewed study
DOI
10.18632/oncotarget.25349
Catalogue ID
BFmoakvgtl-3qzdq7
Pulse AI · ask about this record

Dig deeper with Pulse AI.

Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.